Evidence map›Paper›PMID 27482351›Full record

ArticleIranian journal of basic medical sciences2016

The protective effect of infliximab against carbon tetrachloride-induced acute lung injury.

Aysel Kurt, Levent Tumkaya, Suleyman Yuce, Hasan Turut, Medine Cumhur Cure, Ibrahim Sehitoglu, Yildiray Kalkan, Gokhan Pusuroglu, Erkan Cure

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of basic medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Aysel KurtRecep Tayyip Erdogan University, School of Medicine, Department of Thoracic Surgery, Rize, Turkey.
Levent TumkayaRecep Tayyip Erdogan University, School of Medicine, Department of Histology and Embryology, Rize, Turkey.
Suleyman YuceDepartment of Internal Medicine, Ordu Kumru State Hospital, Ordu, Turkey.
Hasan TurutRecep Tayyip Erdogan University, School of Medicine, Department of Thoracic Surgery, Rize, Turkey.
Medine Cumhur CureRecep Tayyip Erdogan University, School of Medicine, Department of Biochemistry, Rize, Turkey.
Ibrahim SehitogluRecep Tayyip Erdogan University, School of Medicine, Department of Pathology, Rize, Turkey.
Yildiray KalkanRecep Tayyip Erdogan University, School of Medicine, Department of Histology and Embryology, Rize, Turkey.
Gokhan PusurogluRecep Tayyip Erdogan University, School of Medicine, Department of Internal Medicine, Rize, Turkey.
Erkan CureRecep Tayyip Erdogan University, School of Medicine, Department of Internal Medicine, Rize, Turkey.
Recep Tayyip Erdoğan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCarbon tetrachloride (CCl4) causes pulmonary toxicity. Infliximab (Ib) is a potent inhibitor of tumor necrosis factor-alpha (TNF-α). We aimed to investigate whether Ib has a protective effect on CCl4 induced lung injury. MATERIALS AND

methodsRats were divided into control, CCl4, and CCl4+Ib groups. A single dose of 2 ml/kg CCI4 was administered to CCI4 group and a single dose of 7 mg/kg Ib was given to CCl4+Ib group 24 hr before applying CCI4.

resultsTNF-α, malondialdehyde (MDA), nitric oxide (NO) and caspase-3 levels of the CCl4 group were markedly higher than both the control and CCl4+Ib groups. The CCI4+Ib group had lower histopathological injury than the CCl4 group.

conclusionIb as a strong TNF-α blocker decreases the production of proinflammatory cytokines, MDA, and oxidative stress leading to a protective effect against CCl4 induced lung tissue injury.

Indexed as

Carbon tetrachlorideInfliximabNitric oxideOxidative stressPulmonary toxicity

Identifiers

PMID27482351
PMCPMC4951609
OpenAlexW2468957277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.